Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2009. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of insider share transactions rather than a financial performance report.
Material Changes
The filing details the acquisition of Ordinary shares by eight individuals on October 9, 2009, at a price of £12.40 per share through the Company's Share Reward Plan. Each individual acquired 10 shares via the partnership element (personal contribution) and 10 shares via the matching element (Company contribution). The individuals involved are Mr. A P Witty, Mr. J S Heslop, Mr. S M Bicknell, Mr. E J Gray, Mr. S A Hussain, Mr. D Learmouth, Mr. D S Redfern, and Ms. C Thomas.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly adheres to Disclosure and Transparency Rule 3.1.4R(1)(a) regarding the notification of share interest changes.
Investor Verification Points
- Verify the share price of £12.40 per Ordinary share on October 9, 2009.
- Confirm the total number of shares acquired by each listed director (20 shares per person: 10 personal, 10 matched).
- Review the terms of the Company's Share Reward Plan to understand the matching contribution mechanism.
- Note that this filing does not contain financial performance data for the period.